Monitoring the Level of C-Labelled Selegiline Following Oral Administration

Overview

Journal Open Med Chem J

Publisher Bentham Open

Specialty Biochemistry

Date 2017 Jun 2

PMID 28567124

Authors

Huba Kalasz

Kornelia Tekes

Erzsebet B Faigl

Zita Postenyi

Eszter Berekmeri

Gellert Karvaly

Ernest Adeghate

Affiliations

Soon will be listed here.

Abstract

Background: Selegiline [(-)-deprenyl] is widely used for the treatment of Parkinson's disease in humans.

Objective: Time-dependence of tissue distribution of selegiline following per os administration to rats.

Method: Oral administration of radiolabeled selegiline to rats resulted in a pattern of tissue distribution similar to that following intraperitoneal injection. Analyses were done using both reversed-phase HPLC and also by counting radioactivity in various body compartments of rats.

Results: As a consequence of oral administration of 30 mg/kg of selegiline, its level in the stomach was extremely high (179.57 µg/g tissue through 54.67 µg/g at 15 min to 120 min), that is one magnitude higher than that in the serum level. High selegiline concentrations were also detected in the lacrimal glands (7.45 µg/g), kidneys (6.87 µg/g), livers (6.01 µg/g) and lungs (3.47 µg/g) after 30 minutes of application, which were higher than after intraperitoneal injections.

Conclusion: The relatively high tissue levels remained for 120 min monitoring. Selegiline levels in the brain (1.69 µg/g) and in the testes (1.88 µg/g) were also considerably higher than following intraperitoneal administration during the entire period of observation (15 to 120 min).

References

Jiang X, Bukhari I, Zheng W, Yin S, Wang Z, Cooke H . Blood-testis barrier and spermatogenesis: lessons from genetically-modified mice. Asian J Androl. 2014; 16(4):572-80. PMC: 4104086. DOI: 10.4103/1008-682X.125401. View

Yen T, Dallo J, Knoll J . The aphrodisiac effect of low doses of (-) deprenyl in male rats. Pol J Pharmacol Pharm. 1982; 34(5-6):303-8. View

Budni P, Martins de Lima M, Polydoro M, Moreira J, Schroder N, Dal-Pizzol F . Antioxidant effects of selegiline in oxidative stress induced by iron neonatal treatment in rats. Neurochem Res. 2007; 32(6):965-72. DOI: 10.1007/s11064-006-9249-x. View

Kalasz H, Kerecsen L, Knoll J, Pucsok J . Chromatographic studies on the binding, action and metabolism of (-)-deprenyl. J Chromatogr. 1990; 499:589-99. DOI: 10.1016/s0021-9673(00)97003-1. View

Harsing Jr L, Vizi E . Release of endogenous dopamine from rat isolated striatum: effect of clorgyline and (-)-deprenyl. Br J Pharmacol. 1984; 83(3):741-9. PMC: 1987073. DOI: 10.1111/j.1476-5381.1984.tb16228.x. View

Tekes K, Magyar K . Effect of MAO inhibitors on the high-affinity reuptake of biogenic amines in rat subcortical regions. Neurobiology (Bp). 2001; 8(3-4):257-64. View

Mruk D, Cheng C . The Mammalian Blood-Testis Barrier: Its Biology and Regulation. Endocr Rev. 2015; 36(5):564-91. PMC: 4591527. DOI: 10.1210/er.2014-1101. View

Hornykiewicz O . The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl. 2006; (70):9-15. DOI: 10.1007/978-3-211-45295-0_3. View

Dallo J, Knoll J . Effect of (-)-para-fluoro-deprenyl on survival and copulation in male rats. Acta Physiol Hung. 1992; 79(2):125-9. View

10.

Urry R, Dougherty K, COCKETT A . Age-related changes in male rat reproductive organ weights and plasma testosterone concentrations after administration of a monoamine oxidase inhibitor. Fertil Steril. 1976; 27(11):1326-34. DOI: 10.1016/s0015-0282(16)42204-1. View

11.

Knoll J . The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech Ageing Dev. 1988; 46(1-3):237-62. DOI: 10.1016/0047-6374(88)90128-5. View

12.

Ehringer H, Hornykiewicz O . [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960; 38:1236-9. DOI: 10.1007/BF01485901. View

13.

Kitani K, Kanai S, Ivy G, Carrillo M . Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models. Ann N Y Acad Sci. 1999; 854:291-306. DOI: 10.1111/j.1749-6632.1998.tb09910.x. View

14.

Magyar K, Knoll J . Selective inhibition of the "B form" of monoamine oxidase. Pol J Pharmacol Pharm. 1977; 29(3):233-46. View

15.

Knoll J . Sexual performance and longevity. Exp Gerontol. 1997; 32(4-5):539-52. DOI: 10.1016/s0531-5565(96)00157-x. View

16.

Muller W, Wollert U . Human serum albumin as a 'silent receptor' for drugs and endogenous substances. Pharmacology. 1979; 19(2):59-67. DOI: 10.1159/000137289. View

17.

Nag S, Varrone A, Toth M, Thiele A, Kettschau G, Heinrich T . In vivo evaluation in cynomolgus monkey brain and metabolism of [¹⁸F]fluorodeprenyl: a new MAO-B pet radioligand. Synapse. 2011; 66(4):323-30. DOI: 10.1002/syn.21514. View

18.

Szoko E, Kalasz H, Kerecsen L, Magyar K . Binding of (-) deprenyl to serum proteins. Pol J Pharmacol Pharm. 1984; 36(4):413-21. View

19.

Gerber J, Heinrich J, Brehm R . Blood-testis barrier and Sertoli cell function: lessons from SCCx43KO mice. Reproduction. 2015; 151(2):R15-27. DOI: 10.1530/REP-15-0366. View

20.

Gaziri L, LADOSKY W . Monoamine oxidase variation during sexual differentiation. Neuroendocrinology. 1973; 12(4):249-56. DOI: 10.1159/000122174. View